Pfizer Tops Q1 Forecasts on Eliquis Strength, Reaffirms 2026 Outlook

Overview

• Pfizer beat expectations with adjusted earnings of $0.75 per share and revenue of $14.5 billion, helped by strong demand for Eliquis, its blood thinner.
• Net income fell to $2.7 billion, a 9% drop from a year ago, and diluted earnings per share slipped 10% to $0.47.
• The company kept its 2026 targets, guiding to adjusted EPS of $2.80 to $3.00 and revenue of $59.5 billion to $62.5 billion.
• Executives said there will be no share buybacks in 2026 and highlighted oncology and obesity programs as key areas of momentum.
• CFO David Denton said revenue from newer and acquired products grew about 22%, part of a plan that also includes deals to delay some generics, such as on Vyndaqel, to ease a patent cliff before 2030.